AdvanCell Establishes U.S. Global Headquarters in Greater Boston, Expands Manufacturing Footprint to Support Radiopharmaceutical Growth
AdvanCell, a clinical-stage radiopharmaceutical company focused on developing targeted alpha therapies for cancer, has announced a major step in its global expansion strategy with the establishment of its U.S. Global Headquarters in the Greater Boston area. Alongside the new headquarters, the company has signed a lease for a 128,000-square-foot facility in Andover, Massachusetts, which will serve as its flagship U.S. manufacturing center and a central component of its long-term clinical and commercial growth plans.
The move represents a significant milestone for AdvanCell as it evolves into a U.S.-based radiopharmaceutical company with integrated operations across North America and Australia. The new site is expected to support the company’s efforts to advance its pipeline of Lead-212 targeted alpha therapies, including ADVC001, while also laying the groundwork for future commercial-scale production in the United States.
Building a U.S. Platform for Long-Term Growth
The expansion into Greater Boston reflects AdvanCell’s broader ambition to strengthen its presence in the United States and establish the infrastructure required to support both late-stage development and eventual commercialization of its radiopharmaceutical programs. As targeted alpha therapy continues to gain momentum as a promising cancer treatment modality, manufacturing capacity and geographic reach are becoming increasingly important competitive factors for companies operating in the space.
By establishing its U.S. Global Headquarters and manufacturing operations in Massachusetts, AdvanCell is positioning itself closer to one of the world’s most established life sciences ecosystems. Greater Boston is home to a dense concentration of biotechnology companies, research institutions, clinical centers, and specialized talent, making it a strategic location for companies seeking to accelerate development, expand partnerships, and prepare for commercial execution.
The company’s new facility will be located at Innovation Park, a campus owned by IQHQ, and is expected to serve a dual role. In addition to housing AdvanCell’s U.S. corporate operations, the site will also become the company’s first internal manufacturing facility in the United States, bringing advanced production capabilities under AdvanCell’s direct control.
This combination of headquarters and manufacturing infrastructure is intended to create a more integrated operating model for the company as it moves its pipeline forward and scales its global footprint.
Supporting ADVC001 and the Lead-212 Pipeline
AdvanCell’s investment in U.S. infrastructure is closely tied to the advancement of ADVC001 and its broader Lead-212 targeted alpha therapy portfolio. The company is developing radiopharmaceutical therapies designed to deliver alpha-emitting isotopes directly to cancer cells, with the goal of improving efficacy while limiting damage to surrounding healthy tissue.
Targeted alpha therapies have drawn growing attention across oncology because of their potential to deliver highly potent radiation over a short range, which may allow for more precise tumor cell destruction. AdvanCell is among a number of radiopharmaceutical developers seeking to build differentiated platforms around these therapies, and the company’s decision to expand manufacturing capabilities in the United States reflects the increasing importance of supply chain control, production scalability, and geographic flexibility in this field.
The Andover facility is expected to play a central role in that strategy. Once operational, it will provide the company with a foundation for scaling production to support anticipated clinical and commercial demand in the U.S. market. This is especially important as AdvanCell advances its programs into later-stage development, where reliable access to manufacturing capacity becomes essential for patient enrollment, regulatory execution, and future launch readiness.
According to the company, the site will act as a cornerstone of its U.S. expansion efforts and will support the long-term growth of its targeted alpha therapy business.
Leadership Sees Facility as Key to Vertical Integration Strategy
AdvanCell CEO Philina Lee, PhD, described the new headquarters and manufacturing site as a defining moment in the company’s growth and a critical part of its ambition to become a fully integrated global targeted alpha therapy company.
Lee said the establishment of AdvanCell’s U.S. Global Headquarters and future manufacturing center underscores the company’s commitment to expanding in the United States while also advancing a broader strategy centered on vertical integration. As AdvanCell continues to progress ADVC001 and its Lead-212 pipeline, she noted that the Andover site will provide a foundation for internal manufacturing in the U.S. and help the company scale production to meet future clinical and commercial requirements.
At the same time, Lee emphasized that AdvanCell’s Australian operations will remain an important part of the company’s broader model. The company plans to continue leveraging capabilities developed in Australia, including its strengths in rapid clinical translation, isotope supply, and process innovation. Those capabilities, combined with a growing U.S. operational and manufacturing base, are intended to support the development of AdvanCell’s targeted alpha therapies for patients globally.
The result is a cross-continental operating structure that links Australian expertise and supply capabilities with a U.S.-based commercial and manufacturing platform. For a radiopharmaceutical company operating in a technically demanding field, that integrated model may provide both strategic flexibility and operational resilience.
Expanding U.S. Manufacturing Through Internal and External Capacity
In addition to fitting out and qualifying the Andover site, AdvanCell is also pursuing a parallel manufacturing strategy aimed at accelerating near-term access to U.S.-based production capacity. As part of that plan, the company is working with a leading contract development and manufacturing organization (CDMO) to establish drug product manufacturing capabilities.
This approach gives AdvanCell a dual-track pathway: it can build out its own long-term manufacturing infrastructure while also using external capacity to support ongoing clinical development and near-term operational needs. For a clinical-stage radiopharmaceutical company, this can be an important way to reduce execution risk and maintain program momentum while permanent facilities are being prepared.
The company said this strategy is expected to support Phase 2 enrollment in the U.S. for the TheraPb study (NCT05720130), while also helping bridge the path toward larger-scale Phase 3 and eventual commercial manufacturing. By combining CDMO support with internal facility development, AdvanCell aims to create a manufacturing network capable of supporting both present clinical activity and future market needs.
This is a notable consideration in radiopharmaceutical development, where manufacturing timelines, isotope handling, regulatory controls, and logistical coordination can be particularly complex. Establishing U.S.-based capacity not only supports clinical execution but may also become increasingly important as companies prepare for commercialization and seek to serve a broader patient population efficiently.
Greater Boston Chosen as Strategic Base for Expansion
AdvanCell’s choice of Greater Boston is consistent with a broader trend among biopharmaceutical and radiopharmaceutical companies that are building operations near established innovation hubs. The region offers proximity to academic institutions, specialized workforce talent, hospital networks, and a mature life sciences infrastructure that can support everything from R&D and clinical development to manufacturing and commercialization.
For AdvanCell, locating its U.S. headquarters and manufacturing center in this environment may help facilitate recruitment, partnerships, and long-term scaling. It also places the company in a region with strong access to investors, service providers, and collaborators that can support the next phase of growth.
The Andover facility itself is expected to anchor AdvanCell’s U.S. presence for years to come. Beyond its immediate function as a manufacturing site, it symbolizes the company’s transition from an emerging clinical-stage player with Australian roots into a more globally structured radiopharmaceutical business with a growing footprint in the United States.
Positioning for the Next Phase of Radiopharmaceutical Development
AdvanCell’s announcement comes at a time when interest in radiopharmaceuticals and targeted alpha therapies continues to rise across the oncology landscape. As more companies seek to bring novel radioisotope-based therapies into the clinic and eventually to market, manufacturing readiness and supply infrastructure are becoming increasingly central to strategic success.
By establishing a U.S. headquarters, securing a large-scale manufacturing site, and pursuing additional CDMO support, AdvanCell is making a clear investment in the operational backbone required to advance its pipeline. The company is not only expanding geographically but also building the capabilities needed to support later-stage development and future commercialization in one of the world’s largest oncology markets.
With ADVC001 and its Lead-212 targeted alpha therapy platform at the center of its growth strategy, AdvanCell is seeking to create a fully integrated model that combines scientific innovation with manufacturing strength and global operational reach. The Andover expansion marks an important step in that journey, giving the company a stronger base from which to scale its radiopharmaceutical programs and pursue broader opportunities in cancer treatment.
About 212Pb-ADVC001
212Pb-ADVC001 (ADVC001) is a proprietary and patented PSMA-targeting radioligand with optimized physicochemical properties and labelled with Lead-212 (212Pb), an alpha-emitting payload (radionuclide) with a high dose rate, 10.6-hour half-life and simple decay scheme. ADVC001 is designed to deliver radiation at a cellular level to effectively kill prostate cancer cells while minimizing toxicity.
About the TheraPb trial
The TheraPb trial (NCT05720130) is a prospective, open-label Phase 1/2 dose escalation and expansion study evaluating ADVC001 in metastatic prostate cancer. The completed Phase 1b dose escalation assessed the safety and tolerability of escalating doses of ADVC001 administered every 6, 4, 2 or 1 week(s) (see press release). The Phase 2 expansion is assessing the efficacy and safety of ADVC001 at two dose levels. The trial utilizes a randomized dose-response design and dose optimization elements to evaluate ADVC001 in PSMA-positive mCRPC and in mHSPC.
About AdvanCell
AdvanCell is a vertically integrated, clinical-stage radiopharmaceutical company dedicated to developing innovative cancer therapies that harness the power of targeted alpha-emitting radionuclides. By leveraging its proprietary Lead-212 platform, advanced and scalable manufacturing and world-class clinical development capabilities, AdvanCell aims to deliver novel treatments that improve outcomes for patients with cancer globally.
